Lumos Diagnostics Holdings Limited (LDXHF)

Market Cap	143.97M +584.2%
Revenue (ttm)	12.40M +11.4%
Net Income	-7.18M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	104,239
Open	0.1692
Previous Close	0.1692
Day's Range	0.1692 - 0.1692
52-Week Range	0.0100 - 0.2105
Beta	0.54
RSI	47.97
Earnings Date	Feb 26, 2026

About LDXHF

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: LDXHF

Financial Performance

In fiscal year 2025, LDXHF's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.